See more : India Pesticides Limited (IPL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aroundtown SA (0RUH.L) Income Statement Analysis – Financial Results
- Tanger Inc. (0LD4.L) Income Statement Analysis – Financial Results
- Sumitomo Corporation (SSUMY) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. Red (CRHC-WT) Income Statement Analysis – Financial Results
- V.I.P. Industries Limited (VIPIND.NS) Income Statement Analysis – Financial Results
Intra-Cellular Therapies, Inc. (ITCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | 0.00 | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
| Cost of Revenue | 33.75M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
| Gross Profit Ratio | 92.73% | 91.79% | 90.17% | 91.59% | -687.16% | 0.00% | -32,205.56% | -28,273.44% | -52.82% | -3,576.82% | -741.34% | -396.68% |
| Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| General & Administrative | 317.66M | 272.98M | 190.11M | 150.06M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Selling & Marketing | 92.20M | 85.80M | 82.50M | 36.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Other Expenses | 0.00 | -1.18M | -2.10M | -282.23K | 0.00 | 0.00 | -245.84K | -330.70K | -60.71K | -29.76K | 0.00 | 0.00 |
| Operating Expenses | 590.01M | 492.32M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
| Interest Expense | 0.00 | 7.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.78K | 0.00 | 7.07K | 612.96K | 193.50K |
| Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |
| EBITDA | -158.85M | -262.97M | -285.16M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| EBITDA Ratio | -34.21% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -40,203.17% | -34,872.43% | -115,815.85% | -5,314.87% | -957.76% | -523.31% |
| Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
| Operating Income Ratio | -34.32% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -41,832.65% | -35,759.96% | -115,815.85% | -5,367.52% | -959.69% | -526.09% |
| Total Other Income/Expenses | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.90M | 1.02M | 296.86K | -583.35K | -154.50K |
| Income Before Tax | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Income Before Tax Ratio | -29.94% | -102.86% | -347.73% | -1,007.48% | -243,711.05% | 0.00% | -40,203.17% | -34,883.55% | -114,696.75% | -5,316.09% | -981.01% | -531.04% |
| Income Tax Expense | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
| Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Net Income Ratio | -30.08% | -102.86% | -347.73% | -1,007.54% | -243,713.69% | 0.00% | -39,771.64% | -35,205.79% | -114,698.50% | -5,316.37% | -981.67% | -532.10% |
| EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| Weighted Avg Shares Out | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Weighted Avg Shares Out (Dil) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Source: https://incomestatements.info
Category: Stock Reports